1. FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction
- Author
-
Juliette Tennenbaum, Matthieu Groh, Laura Venditti, France Campos-Gazeau, Emilie Chalayer, Thomas De Broucker, Mohamed Hamidou, Mathilde Hunault, Aicha Lyoubi, Raphaëlle Meunier, Thierry Muron, Damien Sène, Borhane Slama, Céline Guidoux, Guillaume Lefèvre, Jean-Emmanuel Kahn, Christian Denier, and Julien Rohmer
- Subjects
Adult ,Male ,0301 basic medicine ,TOAST Classification ,medicine.medical_specialty ,Receptor, Platelet-Derived Growth Factor alpha ,Oncogene Proteins, Fusion ,Hypereosinophilia ,03 medical and health sciences ,0302 clinical medicine ,Recurrence ,Internal medicine ,Hypereosinophilic Syndrome ,medicine ,Humans ,Stroke ,Ischemic Stroke ,Retrospective Studies ,mRNA Cleavage and Polyadenylation Factors ,Advanced and Specialized Nursing ,First episode ,business.industry ,Hypereosinophilic syndrome ,Coronary Thrombosis ,Brain ,Retrospective cohort study ,Cerebral Infarction ,Middle Aged ,medicine.disease ,Treatment Outcome ,030104 developmental biology ,Imatinib mesylate ,Imatinib Mesylate ,Etiology ,Female ,Neurology (clinical) ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,030217 neurology & neurosurgery ,Follow-Up Studies - Abstract
Background and Purpose: Ischemic stroke has been reported in various conditions associated with eosinophilia. FIP1L1-PDGFRA fusion ([Fip1-like 1-platelet-derived growth factor receptor alpha]; F/P ) leads to the proliferation of the eosinophilic lineage and thus to a clonal hypereosinophilic syndrome that is highly responsive to imatinib. Methods: We previously reported on a nationwide retrospective study of 151 patients with F/P -associated clonal hypereosinophilic syndrome. Patients from this cohort with a clinical history of ischemic stroke (as well as 2 additional cases) were further analyzed to better define their clinical picture and outcomes. Results: Sixteen male patients (median age, 51 [43–59] years) with low-to-intermediate cardiovascular risk were included. Median National Institutes of Health Stroke Scale was 4 (range, 1–6). Most cerebral imaging disclosed multiple bilateral infarctions of watershed distribution (69%). Despite frequent cardiac involvement (50%), cardiac thrombus was evidenced in a single patient and, according to the TOAST classification (Trial of ORG 10172 in Acute Stroke Treatment), 62.5% of strokes were presumably of undetermined etiology. Among the 15 patients treated with imatinib, and after a median follow-up of 4.5 years, stroke recurred in only 3 patients (consisting of either cardio embolic or hemorrhagic events, unrelated to the first episode). Conclusions: F/P + clonal hypereosinophilic syndrome is a diagnosis to consider in patients with unexplained ischemic stroke and hypereosinophilia (especially in the setting of multiple cortical borderzone distribution) and warrants prompt initiation of imatinib.
- Published
- 2021
- Full Text
- View/download PDF